Bayer's Pipeline Momentum Faces Its Courtroom Deadline

FDA broadened Hyrnuo to first-line HER2-mutant NSCLC on Sept 9; Bayer also advances Kerendia filing and a EUR 3 billion Apollo deal.

Bayer's oncology franchise picked up meaningful ground this month when U.S. regulators broadened the label for Hyrnuo, the company's targeted lung cancer therapy. The FDA's September 9 decision allows sevabertinib to be used as a first-line treatment for adults with locally advanced or metastatic HER2-mutant non-small cell lung cancer, lifting an earlier restriction that had confined the drug to patients who had already undergone prior therapy.

That shift from second-line to front-line use widens the eligible patient pool considerably in one of oncology's most closely watched niches — a welcome development for a pharma division under pressure to deliver fresh growth beyond its established blockbusters.

Equity markets took the news in stride. Analysts pointed to a combination of factors supporting the stock: clinical momentum behind Hyrnuo, progress on the kidney drug Kerendia, a steady agricultural business, and the gradual fading of glyphosate-related liabilities from the investment narrative.

A Tale of Two Ticks

The share price told a more nuanced story than the headlines suggested. Bayer stock most recently changed hands at EUR 49.20, up 1.1% on the session, according to one reading of the tape. A separate snapshot from the prior day's close showed the stock at EUR 48.69, down 1.1%. Year-to-date, the DAX-listed equity has climbed roughly 32% to 33%, reflecting the market's tentative endorsement of management's turnaround efforts.

Pipeline Milestones Pile Up

The Hyrnuo approval is not an isolated event. Roughly two weeks earlier, Bayer filed for regulatory clearance in Japan for Kerendia as a treatment for non-diabetic chronic kidney disease, backed by positive data from the Phase III FIND-CKD trial. The therapy is already approved for diabetic kidney disease in more than 100 countries.

Further out, the company's May 2026 agreement to acquire Perfuse Therapeutics — for up to USD 2.45 billion, including USD 300 million upfront plus contingent milestone payments — adds ophthalmology assets to the development pipeline, broadening the mid-term growth story beyond oncology and kidney care.

The Balance Sheet Gets a Haircut

On the financing side, Bayer has engineered additional breathing room through portfolio adjustments. Apollo Global Management's entry as a minority owner of a newly created entity housing the company's long-acting reversible contraceptive business will inject EUR 3 billion of equity into the group. Operational control stays with Bayer.

The transaction prompted management to revise its year-end net financial debt forecast downward, from a prior range of EUR 32 to 33 billion to EUR 29 to 30 billion. Closing is expected in the third quarter of 2026, and the proceeds are earmarked as the financial bedrock for future pipeline investments.

For the full year, Bayer reaffirmed guidance of adjusted EBITDA between EUR 9.6 and 10.1 billion, alongside adjusted earnings per share of EUR 4.30 to EUR 4.90.

Missouri Holds the Wildcard

Running parallel to these operational wins is the legal front, where the stakes remain substantial. On the most recent Monday, a Missouri court held a hearing on final approval of Bayer's proposed USD 7.25 billion glyphosate settlement. A ruling is expected before year-end.

The company has already secured some legal tailwinds. On June 25, the U.S. Supreme Court ruled 7-2 that federal preemption takes precedence over state law in relevant claims. On August 27, the Eighth Circuit Court of Appeals rejected a related challenge. Together, these decisions have narrowed the field of remaining litigation.

What Could Go Wrong

The primary risk is delay. Should the Missouri judge attach additional conditions to final approval or permit new appeals, legal uncertainty would persist — tying up management bandwidth and keeping the stock's risk premium elevated.

Commercial execution poses a second challenge. Despite the FDA green light, sevabertinib must still win over oncologists accustomed to entrenched treatment standards. Kerendia's Japanese filing is likewise subject to regulatory scrutiny and is no foregone conclusion.

A third vulnerability lies in timing. If the EUR 3 billion Apollo transaction slips beyond the current quarter, the projected reduction in net financial debt to EUR 29-30 billion would be pushed back, leaving interest costs to weigh on group earnings for longer than planned.

The Road Ahead

As long as the Apollo deal closes on schedule in Q3 2026 and net debt trends toward the targeted range, the fundamental repair of Bayer's balance sheet stays on track. The stock's roughly 32% gain since January suggests investors are willing to extend some credit for that consolidation path. But any slippage in the deleveraging timeline — or unexpected hurdles in Missouri — could stall the re-rating story before it gains full traction. The next major catalysts are the Missouri court's final approval decision on the glyphosate settlement and confirmation that the Apollo transaction has financially closed before the quarter ends.